The purpose of this study was to assess adherence to vascular protection drugs in diabetic patients using a cohort of diabetic patients aged ≥30 years, covered by the public drug insurance in the province of Quebec, excluding gestational diabetes and patients who were hopitalized or died during the 1-year follow-up. Drug adherence was measured using the medication possession ratio. Multivariate analyses, including logit and multinomial logit were used. Of the 170,381 diabetics (mean age: 62 ± 14 years), 18% and 32% were regular users of ASA and ACEIs/ARBs, respectively. Regular use increased with age (p<0.0001) and comorbidities (p<0.0001). Rural inhabitants were more likely to use ACEIs/ARBs (OR: 1.29; 95% CI: 1.26-1.32) and to be regular users (OR: 1.36; 95% CI: 1.32-1.39). Similar results were found for ASA. In conclusion, despite the high cardiovascular risks associated with diabetes, less than one-third of diabetic adults took vascular-protection drugs regularly. This important issue needs proper attention.
Introduction
Despite evidence-based guidelines for vascular protection medication (aspirin (ASA), angiotensin-converting enzyme inhibitor (ACEI) and angiotensin II receptor blocker (ARB)) in diabetic patients, 1-3 the transfer of recommendations into practice is not always optimal. [4] [5] [6] One factor responsible is poor adherence to prescribed medication regimens. 5 Recent methodological progress provides measures for estimating medication adherence from pharmacy claims data. 6, 7 The medication possession ratio (MPR) is often defined as the sum of the days' supply of medication divided by the number of days between the first fill and last refill. This calculation results in a percentage between 0 and 100% to quantify adherence. 6, 7 Several factors may influence adherence to medications. However, age, gender and place of residence fail to correlate consistently with adherence. 4, 5, 8 In this study, we aimed to determine the level of adherence to the recommended vascular-protection drugs (ASA and ACEIs/ARBs) using MPR in diabetic patients and the factors associated with vascular-protection medication use.
Study population
The study population was an exhaustive cohort of diabetic patients from 1999 to 2002. The diabetes cases were defined using the definition given by the Canadian National Diabetes Surveillance System a (NDSS). The studied population included all diabetic patients aged 30 years or older (highrisk patients according to the Canadian Clinical Guidelines for diabetes in 1998 2 ) covered by the public drug-insurance plan. The date of the first health service claim reporting a diagnosis of diabetes during the study period was defined as the index date. The subjects were followed for 1 year after the index date. Exclusion criteria were patients for whom data related to the place of residence was missing, women with gestational diabetes, and patients who died or were hospitalized during the follow-up period.
Drug exposure
Vascular protection drugs were (1) ASA; and (2) either an ACEI or an ARB 1,2 according to the Canadian guidelines for diabetes treatment published between 1998 and 2003.
Vascular protection drug use was defined as any claim of ASA or ACEIs/ARBs. Dosage modifications of the same drug or change in medication within the same class of drug did not count as a different filled prescription. We followed prescriptions filled by patients in the cohort for 1 year after their index dates and separately examined and analyzed rates of ASA and ACEI/ARB use.
The MPR was used 6, 7 to define the level of drug adherence. The MPR expressed in percentages was used to define the following categories of users according to their levels of adherence: 
Other variables
In order to control the possible confounders in the analysis, sex, age, type of residential area (rural/urban) at the index date, adherence to antidiabetic medications and presence of comorbid conditions such as hypertension and vascular disease that could be associated with vascular-protection use were selected. 5, 8 Age at index date was categorized as 64 years or younger, and 65 years or older. Place of residence at the index date was categorized as rural or urban according to Canada Statistical Area Classification (SAC) and was defined as follows: 10 1. Urban being a metropolitan area (urban core of at least 100,000 people and its adjacent municipalities) or an agglomeration area (urban core of 10,000 to 99,999 people and its adjacent municipalities). 10 2. Rural being an area not included in the former category. 10 The method for using this classification was described in detail in our previous work. 11 Antidiabetic medications were classified according to the Canadian guidelines for diabetes treatment (alphaglucosidase inhibitor; metformin; insulin; sulfonylurea; meglitinide, thiazolidines). 1 The definition of adherence to antidiabetic medications was the same as that used for vascular protection therapies (see above).
Hypertension or vascular disease (defined as any record of ICD-9 code 401 (hypertension), ICD-9 code 410-414 (ischaemic heart disease), ICD-9 code 428 (heart failure) or ICD-9 code 430-438 (cerebrovascular disease)), diagnosed within 3 years before the index date were considered.
Statistical analyses
A descriptive analysis was performed to describe the studied population. Logistic regression models were used to assess the effect of studied variables on the overall vascular-protection medication use (separately for ASA and ACEIs/ARBs). Multinomial logistic regression was used to assess the effects of studied variables on regular use of vascular-protection medication (separately for ASA and ACEIs/ARBs) while comparing the regular users to nonusers and irregular users. Statistical analyses were performed using SAS 9.1.
Ethics
The study was approved by the Research Ethics Committee at the Université de Sherbrooke and by the Commission d'accès à l'information du Québec. p<0.0001, multinomial logit; *Non-significant 2 Adjusted OR for regular users of ASA in patients living in a rural area versus an urban area when compared to non-users is OR: 1.32; 95% CI: 1.28-1.37 and irregular users is OR: 1.14; 95% CI: 1.10-1.18 and for regular users of ACEIs/ARBs when compared to non-users is OR: 1.36; 95% CI: 1.32-1.39 and irregular users is OR: 1.18; 95% CI: 1.14-1.23. 3 Adjusted OR for regular use of ASA in hypertensive patients versus non-hypertensive when compared to non-users is OR1.44; 95% CI: 1.40-1.48 and irregular users is OR: 1.12; 95% CI: 1.08-1.16 and for regular users of ACEIs/ARBs compared to non-users is OR: 5.02; 95% CI: 4.9-5.14 and irregular users is OR: 1.83; 95% CI: 1.77-1.89. 4 Adjusted OR for regular uses of ASA in patients with cardiovascular disease versus without cardiovascular disease when compared with non-users is OR: 6.35; 95% CI: 6.18-6.53 and irregular users is OR: 2.24; 95% CI: 2.15-2.32 and for regular users of ACEIs/ARBs when compared with non-users is OR: 1.67; 95% CI: 1.63-1.71 and irregular user is OR: 1.28; 95% CI: 1.24-1.32.
Results
Of the 170,381 subjects who met the study inclusion and exclusion criteria, 22% (37,569) were living in a rural area, 60% (102,499) were aged 65 years or older (mean±SD age of 62±14 years old) and 52% (89,344) were female. Approximately 47% (79,288) had hypertension and about 31% (52,180) had vascular disease. Only 29% (49,535) did not use any antidiabetic drugs during the study period whereas 51% (86,774) were regular users of at least one antidiabetic drug (data not shown).
Approximately 18% (30,870) used ASA regularly and 10% (16,959) used ASA irregularly. Approximately 32% (55,053) used ACEIs/ARBs regularly and 13% (21,429) used ACEIs/ARBs irregularly ( Table 1 ). Only 14% (9577) used ASA and 25% (16,640) used ACEIs/ARBs without history of hypertension or vascular disease (data not shown). Based on these results, patients were more likely to be treated with an ACEI/ARB than with ASA (45% vs. 28%, respectively).
The result of the logistic regression model shows that women were less likely than men to use ASA (OR: 0.78; 95% CI: 0.77-0.80) and ACEIs/ARBs (OR: 0.97; 95% CI: 0.96-0.99). For both ASA and ACEIs/ARBs, the likelihood of using these medications increased significantly with age (p<0.0001). Patients living in rural areas were significantly more likely to use ASA and ACEIs/ARBs than urban inhabitants (OR: 1.26; 95% CI: 1.22-1.29 for ASA and OR: 1.29; 95% CI: 1.26-1.32 for ACEIs/ARBs). Patients being treated regularly for their diabetes were more likely to be taking ASA (OR 1.56; 95% CI: 1.52-1.61) and ACEIs/ARBs (OR 2.66; 95% CI: 2.59-2.73). Patients with hypertension and vascular disease were more likely to be taking ASA (OR 1.37; 95% CI: 1.35-1.41; and OR 4.72; 95% CI: 4.61-4.83) and ACEIs/ARBs (OR 4.16; 95% CI: 4.07-4.25; and OR 1.56; 95% CI: 1.52-1.59), respectively (data not shown).
Similar results were found for regular users of ASA and ACEIs/ARBs when compared to irregular users and nonusers using multinomial logistic regression. In addition, the 76,482 patients taking ACEIs/ARBs were more likely to take ASA concurrently than those not treated with ACEIs/ ARBs (OR: 1.94; 95% CI: 1.89-1.99) (data not shown).
Discussion
Canadian treatment guidelines recommend vascular riskmodification treatments for all patients with diabetes, including aspirin and ACEIs/ARBs; 1,2 however, the benefits of ASA use in diabetics have not been clearly established. 12 The results of this large-scale retrospective study suggest poor adherence to vascular-protection medication.
This study also revealed lower adherence to vascular-protection medications among residents of urban areas. The studies reported to date show conflicting results. Several studies have shown reduced use of health services and medications by residents of rural areas, 4,10 while other studies suggest that residents of rural areas consistently use less intensive care. 8 Regular users of antidiabetic drugs were more likely to be regular users of at least one of the recommended vascularprotection drugs. This association may reflect the influence of other correlated but unmeasured factors such as behavioural and attitudinal factors that, in a similar way, influence adherence to ASA, ACEIs/ARBs and antidiabetic agents. Qualitative studies of patient adherence to medication and patient-physician relation may help clarify this issue.
This study has some limitations. All data related to drug prescriptions comes from the RAMQ. Prescriptions written but not filled and prescriptions purchased outside the government's health insurance plan were not included in the data. All dispensed medications were included, whether or not the patients used them. Aspirin can be readily purchased 'over-the-counter', so the level of adherence may have been underestimated. Since the public drug-insurance plan covers the cost of this drug when prescribed, the proportion of users of over-the-counter aspirin for vascular protection is probably low.
In conclusion, using an exhaustive cohort of diabetic patients living in Quebec, poor adherence to vascular-protection drugs was detected. Proper interventions should be made to improve vascular-protection in this vulnerable population.
